Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.

Artificial cells, nanomedicine, and biotechnology - 1 Nov 2018

Wang Jin, Chen Yunqing, Xiang Fenggang, Li Min, Li Hong, Chi Jinghua, Ren Keyu

Abstract excerpt

Cisplatin-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but drug resistance occurs in most patients, leading to treatment failure. Recent studies have shown that epithelial-mesenchymal transition (EMT) is associated with drug resistance. However, the underlying mechanism is not entirely clear. In this study, first we showed significant positive correlation between the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to Gene Knockdown Techniques

Share to Lung Neoplasms

Share to Transforming Growth Factor beta1

Source

Identifiers

PMID: 28918673
DOI: 10.1080/21691401.2017.1374285

Genes

ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.PMID 28918673Read ↗

Cisplatin-induced activation of TGF-β signaling contributes to drug resistanceSemantic proximity Read ↗

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.Semantic proximity Read ↗

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin ResistanceSemantic proximity Read ↗

Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.Semantic proximity Read ↗

TGF-β-driven EMT in cancer progression and drug resistanceSemantic proximity Read ↗

Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic StrategiesSemantic proximity Read ↗

TGF-β: An emerging player in drug resistanceSemantic proximity Read ↗

miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting METSemantic proximity Read ↗

Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 CellsSemantic proximity Read ↗

TAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cellsSemantic proximity Read ↗

Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2Semantic proximity Read ↗

Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.